Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARGET: Sumatriptan nasal powder for acute migraine
NCT01462812Phase 3Completed
- Sponsor
- OptiNose
- Start
- Jan 2011
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in migraine comparing Sumatriptan 20 mg with Placebo (2 arms). Primary endpoint: Headache Relief at 120 Minutes. Started Jan 2011; status: completed.
02
Drugs
sumatriptan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT01462812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01462812.